Multiple studies have reported increased expression of both CXCL16 and CXCR6 in advanced stages of prostate cancer as well as in metastatic tissues, with expression pattern correlating with Gleason score of patients [251,252,253,254]. This evidence concerns the gene CXCL16 and prostate carcinoma.